CD44v6 CAR-T Cells Target DNMT3A-Mutant AML: Synergistic Enhancement by Decitabine

This study highlights #CD44v6 as a promising #CARTCellTherapy target in #AML patients with #DNMT3A mutations, suggesting a novel strategy that combines #Epigenetic modulation with CAR T therapy to advance precision treatment in AML. #medsky
Read: doi.org/10.1007/s115...